
Quarterly report 2025-Q3
added 11-03-2025
Biodesix Net Debt 2011-2026 | BDSX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Biodesix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.5 M | -869 K | -36.3 M | - | -46.4 M | 30.7 M | 17.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.7 M | -46.4 M | -3.53 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Co-Diagnostics
CODX
|
-10.6 M | $ 1.27 | -22.09 % | $ 1.69 M | ||
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 15.81 | -2.35 % | $ 478 M | ||
|
Agilent Technologies
A
|
1.24 B | $ 111.6 | -1.45 % | $ 33.9 B | ||
|
Castle Biosciences
CSTL
|
-106 M | $ 19.18 | 1.59 % | $ 556 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Illumina
ILMN
|
-494 M | $ 141.04 | -1.54 % | $ 22.4 B | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.8 | - | $ 7.96 M | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 19.85 | -3.12 % | $ 1.06 B | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-3.13 M | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 93.57 | -3.21 % | $ 6.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 417.23 | -0.46 % | $ 12 B | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 037.75 | -0.4 % | $ 21.4 B | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Myriad Genetics
MYGN
|
-22.8 M | $ 3.62 | -0.14 % | $ 335 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
187 M | $ 8.28 | -0.96 % | $ 1.06 B | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 153.0 | -3.85 % | $ 7.58 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 18.63 | -1.61 % | $ 417 M | ||
|
Natera
NTRA
|
-177 M | $ 188.85 | -4.1 % | $ 18.6 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 25.25 | -0.98 % | $ 23.9 B | ||
|
Guardant Health
GH
|
1.15 B | $ 94.7 | -4.02 % | $ 11.9 B | ||
|
Senseonics Holdings
SENS
|
-4.15 M | $ 5.72 | -1.8 % | $ 239 M | ||
|
Personalis
PSNL
|
-117 M | $ 6.46 | -3.73 % | $ 576 M | ||
|
Soleno Therapeutics
SLNO
|
-19.5 M | $ 53.0 | 0.02 % | $ 2.69 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 117.71 | 0.53 % | $ 9.71 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.36 | -2.12 % | $ 5.42 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 252.45 | -0.62 % | $ 21 B | ||
|
Thermo Fisher Scientific
TMO
|
29.6 B | $ 438.41 | -2.17 % | $ 165 B | ||
|
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.56 | -3.63 % | $ 201 M | ||
|
Celcuity
CELC
|
-28.1 M | $ 135.32 | 0.45 % | $ 6.33 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Twist Bioscience Corporation
TWST
|
-107 M | $ 48.53 | -8.35 % | $ 2.9 B | ||
|
Neogen Corporation
NEOG
|
751 M | $ 8.22 | -2.55 % | $ 1.78 B | ||
|
Waters Corporation
WAT
|
391 M | $ 330.33 | -0.86 % | $ 19.7 B | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 186.95 | -0.53 % | $ 20.8 B |